NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
Federal contract awards classified under NAICS code 541714 (RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)) cover 340 unique federal contracts (432 total action records) from USASpending.gov. The top contractors, awarding agencies, and geographic concentration below are aggregated from the highest-value awards in this market — the right view for sizing competition and identifying incumbents.
Top Contractors in NAICS 541714
Largest recipients of federal contract dollars in this NAICS code (ranked by total obligated value). These are the incumbent competitors to know if you sell into this market.
| Contractor | Awards | Total Obligated |
|---|---|---|
| THE BOEING COMPANY | 1 | $4.4B |
| ALLUCENT GOVERNMENT SERVICES (US) LLC | 2 | $373.2M |
| ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC. | 4 | $342.2M |
| TECHNICAL RESOURCES INTERNATIONAL, INC. | 3 | $323.0M |
| PARATEK PHARMACEUTICALS, INC | 1 | $265.3M |
| GENENTECH INC | 1 | $243.7M |
| PPD DEVELOPMENT LP | 5 | $211.8M |
| L3 TECHNOLOGIES, INC. | 1 | $179.6M |
| ADVANCED TECHNOLOGY INTERNATIONAL | 3 | $136.5M |
| MAPP BIOPHARMACEUTICAL, INC. | 2 | $127.3M |
Top Awarding Agencies
Federal agencies that obligate the most spending in NAICS 541714. Click any agency to see its full contract portfolio, top contractors, and sub-agencies.
| Agency | Awards | Total Obligated |
|---|---|---|
| Department of Defense | 45 | $4.8B |
| Department of Health and Human Services | 166 | $3.3B |
| Department of Veterans Affairs | 71 | $14.7M |
| Department of the Interior | 9 | $14.2M |
| National Aeronautics and Space Administration | 16 | $10.2M |
| Department of Agriculture | 22 | $2.4M |
| Department of Transportation | 1 | $200,000 |
| Smithsonian Institution | 1 | $145,146 |
| Environmental Protection Agency | 2 | $95,084.42 |
| Department of Justice | 1 | $8,444.27 |
Geographic Concentration
States where NAICS 541714 contract work is performed, ranked by total obligated value. Useful for sizing the local market and identifying state-level competitors.
| State | Awards | Total Obligated |
|---|---|---|
| AL | 5 | $4.4B |
| MD | 51 | $605.9M |
| MA | 20 | $589.1M |
| OH | 16 | $385.9M |
| TX | 10 | $382.0M |
| NC | 17 | $334.5M |
| CA | 32 | $331.2M |
| NY | 10 | $199.5M |
| UT | 7 | $194.1M |
| SC | 5 | $133.6M |
Most Recent Awards
JACKSON LABORATORY
NICHD: R&D: TO PRODUCE, POTENTIALLY ACQUIRE, MAINTAIN, AND DISTRIBUTE MOUSE MODELS FOR CYTOGENETIC RESEARCH, SPECIFICALLY MODELS FOR DOWN SYNDROME (HUMAN TRISOMY FOR CHROMOSOME 21): SEVERABLE
JACKSON LABORATORY
NICHD: R&D: TO PRODUCE, POTENTIALLY ACQUIRE, MAINTAIN, AND DISTRIBUTE MOUSE MODELS FOR CYTOGENETIC RESEARCH, SPECIFICALLY MODELS FOR DOWN SYNDROME (HUMAN TRISOMY FOR CHROMOSOME 21): SEVERABLE
EVIMERO, LLC
LEVERAGING THE GUT MICROBIOME AS AN INTEGRATOR OF NUTRITIONAL STATUS: A FEASIBILITY STUDY OF MICROBIOME NUTRITIONAL DIAGNOSTICS (MINU-DX)
MONOGRAM BIOSCIENCES, INC.
HIGH THROUGHPUT SARS-COV-2 NEUTRALIZING ANTIBODY IMMUNOASSAY FOR QUALIFYING VARIANTS AND TESTING OF HUMAN SERUM SAMPLES.
OSSIUM HEALTH, INC.
BONE MARROW CRYO-BANKING TO TREAT ACUTE RADIATION SYNDROME IN A MASS-CASUALTY EMERGENCY
All Unique Contracts in NAICS 541714
Showing 340 unique contracts (one entry per PIID, deduped from modifications) sorted by total dollars obligated.
MICHIGAN TECHNOLOGICAL UNIVERSITY
DDARPA TRIAGE CHALLENGE (DTC) UNDER THE SIGNATURES OF TRAUMA FOR ALGORITHM-ASSISTED CLINICAL ASSESSMENT, TRIAGE, AND OBSERVATION (STACATO) PROGRAM
UNIVERSITY OF OKLAHOMA
BASE IDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS TASK ORDER TITLE: FURTHER DEVELOPMENT OF MITOCHONDRIA-TARGETED HONOKIOL FOR PREVENTION OF LUNG CANCER: ADENOCARCINOMA A
AKINA, INC.
THIS IS A FIRM FIXED PRICE FORNEW PLGA ANALYTICAL METHODS FOR MINI-SIZE COMPLEX LONG-ACTING INJECTABLE FORMULATIONS.
BLUEHALO, LLC
ADVANCED DEVELOPMENT OF OPERATIONAL PERFORMANCE TECHNOLOGIES (ADOPT)
IIT RESEARCH INSTITUTE
TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTION PERIOD OF PERFORMANCE: 09/21/2020 - 03/20/2022
REGENTS OF THE UNIVERSITY OF MICHIGAN
A MOSAIC APPROACH FOR UNDERSTANDING STIMULANT AND OPIOID USE AND USE DISORDER TRAJECTORIES AND ASSOCIATED CONSEQUENCES IN US ADULTS
THE INSTITUTE FOR CANCER RESEARCH
COLORECTAL CANCER (CRC) PREVENTION BY UROLITHIN A IN RODENT CRC MODELS
SOLVUS GLOBAL LLC
RESEARCH AND DEVELOPMENT
INTEGRATED SOLUTIONS FOR SYSTEMS, INC.
RESEARCH AND DEVELOPMENT
MAINSTREAM ENGINEERING CORP
RESEARCH AND DEVELOPMENT
STI LEGACY, INC.
PREPARE A FEASIBILITY ASSESSMENT OF LONG-TERM DEEP SPACE AVATAR RESEARCH OPPORTUNITIES. THESE EXPERIMENTS WILL UTILIZE AUTONOMOUS SYSTEMS ENABLING LONGER TERM SCIENCE OPERATIONS IN DEEP SPACE.
UNIVERSITY OF OKLAHOMA
TASK ORDER TITLE: PREVENTING LUNG ADENOCARCINOMA (LUAD) USING TRAIL INDUCING AGENT, ONC201 BASE CONTRACT TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS
BATTELLE MEMORIAL INSTITUTE
BATTELLE IDIQ
TECHWERKS LLC
RESEARCH AND ANALYSIS OF DEVICES IN ADVANCED DEVELOPMENT
THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER
TARGETING STAT3 TO PREVENT COLORECTAL CANCER SECONDARY TO INFLAMMATORY BOWEL DISEASE
KNOWESIS, INC.
BIOPSYCHOSOCIAL RESEARCH AND ANALYSIS
MRIGLOBAL
DIAGNOSTICS PRE-CLINICAL SERVICES PROGRAM
THE MCCONNELL GROUP, INC.
ANIMAL WELFARE SPECIALIST SERVICES FOLLOW ON.
UNIVERSITY OF OKLAHOMA
TO TITLE: A NOVEL MRNA VACCINE TO PREVENT TRIPLE NEGATIVE BREAST CANCER IDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS
TECHWERKS LLC
NON-PERSONAL SERVICES FOR RESEARCH SUPPORT FOR MILITARY PSYCHIATRY RESEARCH AND ANALYSIS FOR WALTER REED ARMY INSTITUTE OF RESEARCH (WRAIR)
CAPTURE BIOSCIENCE INC.
CAPTURE BIOSCIENCE, INC. R&D FOR BEADS BY TIME-OF-FLIGHT. ISOTOPE-BASED TECHNOLOGY ENABLING HIGHLY SCALABLE MULTIPLEX SEROLOGY. AREA OF INTEREST NO: #23 (HOST-BASED DIAGNOSTICS)
AURAVAX THERAPEUTICS, INC.
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ASSESS THE ABILITY OF AURAVAX THERAPEUTICS? (AURAVAX) NOVEL MUCOSAL ADJUVANT NANOSTING-002, TOGETHER WITH INFLUENZA LIVE ATTENUATED VIRUS (LAV) CREATED WITH CODAGENIX NOVEL SYNTHETIC ATTENUATED VIRUS ENGIN
MACH32 INC
MACH32- DEVELOPMENT OF INTRAMUSCULAR TRANEXAMIC ACID FORMULATION
CLARIVATE ANALYTICS (US) LLC
CLARIVATE ANALYTICS US LLC R&D FOR DEVELOPING MCMS FOR CHEMICAL THREATS USING DRUG REPOSITIONING (AOI #5 REDIRECT)
OSIVAX
OXIVAX - AOI #28: INFLUENZA VACCINE INNOVATION. ADVANCING METAGENOMIC NEXT-GENERATION SEQUENCING BASED AGNOSTIC DIAGNOSTICS FOR VIRAL PATHOGENS THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO PREPARE THE IND PACKAGE FOR OVX836+SQ ADJUVANT.